The myVision® Variant Classification Program has dramatically reduced the VUS rate for Myriad’s genetic tests, which allows the company to continue to provide the most accurate, clinically significant results for your patients.

Decline in Rate of BRCA1/2 Variants of Uncertain Significance

* Large rearrangement testing.